Severe asthma and the omalizumab option
<p>Abstract</p> <p>Atopic diseases and asthma are increasing at a remarkable rate on a global scale. It is now well recognized that asthma is a chronic inflammatory disease of the airways. The inflammatory process in many patients is driven by an immunoglobulin E (IgE)-dependent pr...
Main Authors: | Johnston Chambless, Krishnaswamy Narayanaswamy, Miller Christopher WT, Krishnaswamy Guha |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2008-05-01
|
Series: | Clinical and Molecular Allergy |
Online Access: | http://www.clinicalmolecularallergy.com/content/6/1/4 |
Similar Items
-
The Hoover's Sign of Pulmonary Disease: Molecular Basis and Clinical Relevance
by: Krishnaswamy Guha, et al.
Published: (2008-09-01) -
Omalizumab for Severe Asthma: Beyond Allergic Asthma
by: C. C. Loureiro, et al.
Published: (2018-01-01) -
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
by: S. M. Snelder, et al.
Published: (2017-07-01) -
Omalizumab for the treatment of severe persistent allergic asthma
by: J Jones, et al.
Published: (2009-09-01) -
A review of omalizumab for the management of severe asthma
by: Lin CH, et al.
Published: (2016-07-01)